JP2023526527A - 高シアル化ＩｇＧの調製及び精製 - Google Patents

高シアル化ＩｇＧの調製及び精製 Download PDF

Info

Publication number
JP2023526527A
JP2023526527A JP2022571265A JP2022571265A JP2023526527A JP 2023526527 A JP2023526527 A JP 2023526527A JP 2022571265 A JP2022571265 A JP 2022571265A JP 2022571265 A JP2022571265 A JP 2022571265A JP 2023526527 A JP2023526527 A JP 2023526527A
Authority
JP
Japan
Prior art keywords
hsigg
igg
active portion
enzymatically active
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526527A5 (https=
Inventor
シェーク，ジョン
グラハム，ステフェン
ゾウイ，ラドウアン
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2023526527A publication Critical patent/JP2023526527A/ja
Publication of JP2023526527A5 publication Critical patent/JP2023526527A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022571265A 2020-05-19 2021-05-19 高シアル化ＩｇＧの調製及び精製 Pending JP2023526527A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063026875P 2020-05-19 2020-05-19
US63/026,875 2020-05-19
PCT/US2021/033156 WO2021236769A1 (en) 2020-05-19 2021-05-19 Preparation and purification of hypersialylated igg

Publications (2)

Publication Number Publication Date
JP2023526527A true JP2023526527A (ja) 2023-06-21
JP2023526527A5 JP2023526527A5 (https=) 2025-04-09

Family

ID=78708028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571265A Pending JP2023526527A (ja) 2020-05-19 2021-05-19 高シアル化ＩｇＧの調製及び精製

Country Status (11)

Country Link
US (1) US20230193339A1 (https=)
EP (1) EP4153617A4 (https=)
JP (1) JP2023526527A (https=)
KR (1) KR20230012560A (https=)
CN (1) CN115715296A (https=)
AU (1) AU2021275117A1 (https=)
BR (1) BR112022023377A2 (https=)
CA (1) CA3182023A1 (https=)
CO (1) CO2022018364A2 (https=)
MX (1) MX2022014520A (https=)
WO (1) WO2021236769A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526421A (ja) * 2020-05-19 2023-06-21 モメンタ ファーマシューティカルズ インコーポレイテッド 高シアル化免疫グロブリン

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527761A (ja) * 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
JP2013537546A (ja) * 2010-08-20 2013-10-03 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
US20160024179A1 (en) * 2013-03-15 2016-01-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
JP2016504337A (ja) * 2012-12-20 2016-02-12 メディミューン，エルエルシー イオン交換クロマトグラフィーを使用して高マンノースグリコフォームのレベルを制御する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113604A2 (en) * 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
EP2877589B1 (en) * 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
CN104327180A (zh) * 2013-07-23 2015-02-04 天士力制药集团股份有限公司 一种重组人血小板衍生生长因子bb的纯化方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013527761A (ja) * 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
JP2013537546A (ja) * 2010-08-20 2013-10-03 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
JP2016504337A (ja) * 2012-12-20 2016-02-12 メディミューン，エルエルシー イオン交換クロマトグラフィーを使用して高マンノースグリコフォームのレベルを制御する方法
US20160024179A1 (en) * 2013-03-15 2016-01-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, vol. 112 (11), JPN6025023416, 2015, pages 1297 - 1306, ISSN: 0005614214 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526421A (ja) * 2020-05-19 2023-06-21 モメンタ ファーマシューティカルズ インコーポレイテッド 高シアル化免疫グロブリン
JP7835691B2 (ja) 2020-05-19 2026-03-25 モメンタ ファーマシューティカルズ インコーポレイテッド 高シアル化免疫グロブリン

Also Published As

Publication number Publication date
CA3182023A1 (en) 2021-11-25
CN115715296A (zh) 2023-02-24
AU2021275117A1 (en) 2022-12-01
BR112022023377A2 (pt) 2022-12-20
CO2022018364A2 (es) 2022-12-30
EP4153617A1 (en) 2023-03-29
MX2022014520A (es) 2023-03-03
KR20230012560A (ko) 2023-01-26
EP4153617A4 (en) 2024-11-20
US20230193339A1 (en) 2023-06-22
WO2021236769A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
EP2729482B1 (en) Method for purifying fc-fusion protein
JP7835691B2 (ja) 高シアル化免疫グロブリン
ES2619677T3 (es) Método de separación para anticuerpos fucosilados
Giddens et al. Chemoenzymatic glyco-engineering of monoclonal antibodies
JP2021519590A (ja) 糖タンパク質の製造
JP2012507550A (ja) セラミックヒドロキシアパタイトクロマトグラフィーを使用する酸性タンパク質の精製
US20230357813A1 (en) Hypersialylated immunoglobulin
US20240336946A1 (en) Solid-phase glycan remodeling of glycoproteins
Hsu et al. Successive remodeling of IgG glycans using a solid-phase enzymatic platform
JP2023526527A (ja) 高シアル化ＩｇＧの調製及び精製
US20230374062A1 (en) Methods of making hyper-sialylated immunoglobulin
RU2844159C1 (ru) Получение и очистка гиперсиалилированного igg
US20230303984A1 (en) Enzymes for Sialylation of Glycans
Moh Platforms for in vitro glycoengineering of proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260217